News
WP7-SG3 “Therapeutic medical devices” guideline
This guideline on “Therapeutic medical devices”, with answered comments from the SAG / Public consultation, is the last guideline of WP7 Subgroup 3 in JA2.
WP7 SG2 Core protocol Pilot for AEG available
WP7 Subgroup 2 is pleased to announce the publication of its final deliverable – the Core protocol Pilot for Additional Evidence Generation (AEG). This pilot
WP5 Strand A – Procedure Manual V 4
This document describes processes planned for conducting pilot rapid assessments for pharmaceuticals. Since the Procedure Manual is a living document, further changes can be expected
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment (Core HTA 2)
The Core HTA is available online at the Core Model Online Tool here. Relevant document can be found as a pdf below. The aim of
Training course for all EUnetHTA Stakeholders, Apr. 23rd, 2015
Presentations from the 3rd face to face training course for EUnetHTA Stakeholders organised by JA2WP2; April 23rd, Brussels. Brief introduction to EUnetHTA and its Tools,
The 5th pilot rapid assessment of WP5 JA2 Strand B on “Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation” is now available.
The purpose of the assessment is to address the research question whether the use of the technologies in question is more effective and/or safer than
Structured telephone support (STS) for adult patients with chronic heart failure (Core HTA 3)
The aim of this core HTA was to compare Structured telephone support (STS) for adult patients with chronic heart failure compared to Usual care defined
Publication of a JA2 methodological guideline – Internal validity of non-randomised studies (NRS) on interventions
During Joint Action 1 a methodological guideline on internal validity of randomised studies (RCT) had been elaborated. It was recommended from different sides that EUnetHTA
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment Amended JA1 Guideline Final Nov 2015
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment_Amended JA1 Guideline_Final Nov 2015
Joint Assessment on Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)
The purpose of the assessment is to evaluate Vorapaxar (ZONTIVITY™) for the reduction of cardiovascular events. Final version of the assessment was published in June
